Roche Holding ( RHHBY ) recently announced survival data from its phase III CLEOPATRA study on Perjeta (pertuzumab). Data from the study showed that Perjeta plus Roche’s existing breast
Merck ( MRK ) recently moved its Alzheimer’s disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will evaluate the safety and efficacy of MK-8931, an oral β-amyloid
Last week, Canadian Imperial Bank of Commerce ( CM ) reported its fiscal fourth quarter 2012 (ended October 31) adjusted earnings per share of C$2.04. This was up nearly 15% from the